Spring House

Sep 24, 2023 | frontiersin.org | Janssen Research |Spring House

Alessandro Pocai1* 1Johnson & Johnson Innovative Medicine, Cardiovascular and Metabolism, Janssen Research and Development (United States), United States The final, formatted version of the article will be published soon. Receive an email when it is updated G protein-coupled receptors (GPCRs) have emerged as important drug targets for various chronic diseases, including obesity and diabetes.

Sep 15, 2023 | arthritis-research.biomedcentral.com | Universitätsklinikum Erlangen |Janssen Research |Spring House |Drexel College

Arthritis Research & Therapy volume 25, Article number: 170 (2023) Cite this article The Original Article was published on 16 August 2023 Correction: Arthritis Res Ther 25, 150 (2023) https://doi.org/10.1186/s13075-023-03125-4 Following publication of the original article [1], the authors reported that the corrections were not carried out during the revisions. The corrections are provided below and the changes have been set in bold typeface.

Sep 1, 2023 | bmcgenomics.biomedcentral.com | Janssen Research |Spring House

The samples included in the analysis were pooled from three studies sponsored by Janssen Research & Development, LLC including 54861911ALZ2002 (NCT02260674), a Phase 2a study to evaluate the safety and tolerability of atabecestat (JNJ-54,861,911), an oral BACE1 inhibitor in participants with early Alzheimer’s Disease [17]; 54861911ALZ2004 (NCT02406027, terminated), the long-term extension study of (JNJ-54,861,911) in early Alzheimer’s disease spectrum patients [17]; and...

Apr 6, 2023 | academic.oup.com | Janssen Research |Spring House

What is already known about this topic? • None Guselkumab is a fully human monoclonal antibody that binds and inhibits the p19 subunit of interleukin-23. • None Multiple phase II and III clinical trials have established favourable safety and efficacy profiles for guselkumab in patients with moderate-to-severe plaque psoriasis. What does this study add?